Overcoming resistance to CAR-T therapy in CLL with ibrutinib & venetoclax
0 Views
administrator
07/14/23
Marco Ruella, MD, University of Pennsylvania, Philadelphia, PA, discusses strategies to overcome resistance to CAR-T therapy in chronic lymphocytic leukemia (CLL), commenting on the addition of ibrutinib and venetoclax to CAR-T therapy, and highlighting the use of gene editing techniques to engineer improved CAR-T constructs. This interview took place at the 2022 European Research Initiative on CLL (ERIC) Meeting.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Show more
Facebook Comments
No comments found